Does mismatch negativity have utility for NMDA receptor drug development in depression?
Open Access
- 1 February 2022
- journal article
- research article
- Published by EDITORA SCIENTIFIC in Revista Brasileira de Psiquiatria
- Vol. 44 (1), 61-73
- https://doi.org/10.1590/1516-4446-2020-1685
Abstract
Rapid antidepressant effects associated with ketamine have shifted the landscape for the development of therapeutics to treat major depressive disorder (MDD) from a monoaminergic to glutamatergic model. Treatment with ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, may be effective, but has many non-glutamatergic targets, and clinical and logistical problems are potential challenges. These factors underscore the importance of manipulations of binding mechanics to produce antidepressant effects without concomitant clinical side effects. This will require identification of efficient biomarkers to monitor target engagement. The mismatch negativity (MMN) is a widely used electrophysiological signature linked to the activity of NMDA receptors (NMDAR) in humans and animals and validated in pre-clinical and clinical studies of ketamine. In this review, we explore the flexibility of the MMN and its capabilities for reliable use in drug development for NMDAR antagonists in MDD. We supplement this with findings from our own research with three distinct NMDAR antagonists. The research described illustrates that there are important distinctions between the mechanisms of NMDAR antagonism, which are further crystallized when considering the paradigm used to study the MMN. We conclude that the lack of standardized methodology currently prevents MMN from being ready for common use in drug discovery. Clinical trial registration: This manuscript describes data collected from the following National Institutes of Health (NIH) and Veterans Affairs (VA) studies: AV-101, NCT03583554; lanicemine, NCT03166501; ketamine, NCT02556606.Keywords
This publication has 95 references indexed in Scilit:
- A Neurocomputational Model of the Mismatch NegativityPLoS Computational Biology, 2013
- Modelling Trial-by-Trial Changes in the Mismatch NegativityPLoS Computational Biology, 2013
- Effect of Aripiprazole on Mismatch Negativity (MMN) in SchizophreniaPLOS ONE, 2013
- Modeling Ketamine Effects on Synaptic Plasticity During the Mismatch NegativityCerebral Cortex, 2012
- Glutamatergic Modulation of Auditory Information Processing in the Human BrainBiological Psychiatry, 2012
- Ketamine as a Novel Antidepressant: From Synapse to BehaviorClinical Pharmacology & Therapeutics, 2011
- Impairment in processing visual information at the pre-attentive stage in patients with a major depressive disorder: A visual mismatch negativity studyNeuroscience Letters, 2011
- Dysfunction of processing task-irrelevant emotional faces in major depressive disorder patients revealed by expression-related visual MMNNeuroscience Letters, 2010
- The mismatch negativity: A review of underlying mechanismsClinical Neurophysiology, 2009
- Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosisPsychopharmacology, 2008